Test Price
2,800 AED✅ Home Collection Available
DIABLO Gene (Autosomal Dominant Deafness 64) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Your Trusted Diagnostic Partner in the UAE
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance on result interpretation by DHA-licensed specialists.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This Next-Generation Sequencing test targets the DIABLO gene to confirm autosomal dominant nonsyndromic hearing loss type 64 (DFNA64), enabling precise genetic diagnosis and informed family planning. The test accurately detects all variant types (SNVs, indels, CNVs) within 3–4 weeks using whole blood, extracted DNA, or a dried blood spot on an FTA card.
Pre-Test Information
- Submit a detailed clinical history of hearing loss, including age of onset, audiogram results, and family pedigree.
- A pre-genetic counselling session (provided at no extra cost) is strongly recommended to draw a pedigree chart of family members affected with autosomal dominant deafness.
- No fasting required; continue prescribed medications unless instructed otherwise.
- Acceptable sample types: 3–5 mL whole blood (EDTA tube), extracted DNA (minimum 1 µg), or one drop of blood on an FTA card.
| Feature | Our DIABLO NGS Test | Closest Alternative (Single‑Gene Sanger Sequencing) |
|---|---|---|
| Diagnostic Precision | 99.9% Sensitivity; detects all variant types (SNVs, indels, CNVs) across the entire DIABLO gene | 90‑95% for point mutations only; misses large deletions/duplications |
| Methodology | NGS (Illumina NovaSeq, clinically validated bioinformatics pipeline) | Sanger sequencing, limited to a single exon‑by‑exon approach |
| Turnaround Time | 3 – 4 weeks from sample receipt | 5 – 8 weeks |
Physician Insight & Safety Protocols
“This test offers definitive molecular confirmation of autosomal dominant deafness 64. It is crucial to correlate genetic findings with audiometric and clinical evaluation. A negative result does not exclude other genetic or environmental causes of hearing loss.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403.
Medication Advisory
Important Safety Information
Do not discontinue any prescribed medication without consulting your doctor. This genetic test does not require any lifestyle or medication changes prior to sample collection.
Exclusion & Safety Criteria
When Not to Proceed
- This test is not intended for acute sudden hearing loss, acute ear infection, or vestibular emergencies.
- Minors must be accompanied by a legal guardian; consent obtained per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- If you experience sudden hearing loss with dizziness, vertigo, tinnitus, or facial weakness, seek emergency medical care immediately.
- Individuals on anticoagulant therapy: a standard blood draw is generally safe; however, inform the phlebotomist of all medications.
Patient FAQ & Clinical Guidance
1. What is the DIABLO gene test and who should consider it?
A: This test analyzes the DIABLO gene to confirm autosomal dominant deafness type 64, particularly for individuals with a family history of early-onset hearing loss. It is recommended for children and adults exhibiting progressive sensorineural hearing loss, as well as asymptomatic relatives seeking carrier status and reproductive risk assessment.
2. How is the sample collected and what is the turnaround time?
A: A certified phlebotomist collects a simple blood sample, extracted DNA, or a single drop of blood on an FTA card during your home visit; results are delivered in 3 to 4 weeks. All specimens are transported under ISO‑certified cold‑chain logistics.
3. Do any medications or supplements affect the test result?
A: No routine drugs interfere with the NGS genetic analysis; nonetheless, inform the pre‑test counselor about all prescription medications, over‑the‑counter supplements, and herbal products. Continue all prescribed treatments unless your physician advises otherwise.
UAE Regulatory & Data Privacy Adherence
Compliance with UAE Law
All testing is conducted in strict accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your genetic data is stored on secure, UAE-based servers with end‑to‑end encryption. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Laboratory license: DHA Facility License No. 1143. ISO 9001:2015 Certificate INT/EGQ/2509DA/3139.
Clinical & Logistical Metadata
| Test Name | DIABLO Gene (Autosomal Dominant Deafness 64) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, or dried blood spot (FTA card) |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina NovaSeq |
| ICD-10-CM Code | H90.5 |
| LOINC Code | 48018-6 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians